PPIs Linked to Worse Outcomes With Widely Used Breast Cancer Drug
Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) was linked to higher risks of progression and death among patients with breast cancer, according to a retrospective cohort study from South Korea. Among over 1,300 women, the median clinical progression-free survival (PFS) in the group taking both a PPI and palbociclib was 25.3 months […]
Some NSCLC Patients on ICI Therapy Fare Worse With Proton Pump Inhibitor Use
Proton pump inhibitor (PPI) use was independently associated with worse treatment outcomes in some patients with non-small cell lung cancer (NSCLC) on immune checkpoint inhibitor (ICI) therapy with pembrolizumab (Keytruda), according to a Japanese multicenter cohort study. Among patients with a PD-L1 tumor proportion score (TPS) of 50% or more, a history of PPI use […]